Krishna Tangirala

485 total citations
27 papers, 349 citations indexed

About

Krishna Tangirala is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Krishna Tangirala has authored 27 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Krishna Tangirala's work include Prostate Cancer Treatment and Research (11 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Neonatal Health and Biochemistry (5 papers). Krishna Tangirala is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Neonatal Health and Biochemistry (5 papers). Krishna Tangirala collaborates with scholars based in United States, Belgium and Switzerland. Krishna Tangirala's co-authors include Fred Saad, Celestia S. Higano, Bertrand Tombal, Xiaolong Jiao, Cora N. Sternberg, Oliver Sartor, Kurt Miller, Daniel J. George, Wenhui Wei and Lin Xie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Krishna Tangirala

24 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Krishna Tangirala United States 11 213 103 85 49 46 27 349
Javier Cassinello Spain 14 151 0.7× 49 0.5× 211 2.5× 18 0.4× 67 1.5× 48 444
Aviva G. Asnis-Alibozek United States 5 131 0.6× 28 0.3× 170 2.0× 25 0.5× 117 2.5× 7 489
Jan Lim Canada 12 289 1.4× 35 0.3× 155 1.8× 24 0.5× 18 0.4× 20 453
Andreea Varga Romania 13 118 0.6× 32 0.3× 168 2.0× 52 1.1× 36 0.8× 60 470
Hyong Woo Moon South Korea 11 119 0.6× 34 0.3× 32 0.4× 29 0.6× 68 1.5× 53 341
Pietro Castellan Italy 15 439 2.1× 105 1.0× 98 1.2× 54 1.1× 37 0.8× 37 723
Ho Seok Chung South Korea 10 133 0.6× 17 0.2× 55 0.6× 54 1.1× 25 0.5× 48 320
Stefania Mantarro Italy 11 75 0.4× 45 0.4× 201 2.4× 9 0.2× 60 1.3× 17 470
Giorgia Tema Italy 14 243 1.1× 26 0.3× 64 0.8× 45 0.9× 34 0.7× 72 541

Countries citing papers authored by Krishna Tangirala

Since Specialization
Citations

This map shows the geographic impact of Krishna Tangirala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krishna Tangirala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krishna Tangirala more than expected).

Fields of papers citing papers by Krishna Tangirala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krishna Tangirala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krishna Tangirala. The network helps show where Krishna Tangirala may publish in the future.

Co-authorship network of co-authors of Krishna Tangirala

This figure shows the co-authorship network connecting the top 25 collaborators of Krishna Tangirala. A scholar is included among the top collaborators of Krishna Tangirala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krishna Tangirala. Krishna Tangirala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chow, Clifton, Melissa Lingohr-Smith, Jay Lin, et al.. (2023). Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA. Journal of Comparative Effectiveness Research. 13(1). e230079–e230079. 6 indexed citations
3.
Tangirala, Krishna, et al.. (2022). A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. The Journal of Headache and Pain. 23(1). 54–54. 14 indexed citations
4.
Seminerio, Michael J., Krishna Tangirala, Rinat Ariely, et al.. (2021). US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab (4289). Neurology. 96(15_supplement). 1 indexed citations
5.
McAllister, Peter, Lois Lamerato, Joshua M. Cohen, et al.. (2021). Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. The Journal of Headache and Pain. 22(1). 156–156. 24 indexed citations
6.
7.
George, Daniel J., Oliver Sartor, Kurt Miller, et al.. (2020). Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clinical Genitourinary Cancer. 18(4). 284–294. 119 indexed citations
8.
Shore, Neal D., Celestia S. Higano, Daniel J. George, et al.. (2020). Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 23(4). 680–688. 22 indexed citations
9.
10.
Tangirala, Krishna, et al.. (2019). A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use. PharmacoEconomics - Open. 4(3). 439–447. 12 indexed citations
11.
Tangirala, Krishna, et al.. (2019). Costs and Healthcare Resource Utilization Associated with Hospital Admissions of Patients with Metastatic or Nonmetastatic Prostate Cancer.. PubMed. 12(6). 306–312. 12 indexed citations
12.
Valderrama, Adriana, et al.. (2017). Treatment, healthcare resource utilization, and costs associated with non-metastatic and metastatic castration-resistant prostate cancer: A claims analysis.. Journal of Clinical Oncology. 35(15_suppl). e18341–e18341. 5 indexed citations
13.
Cairo, Mitchell S., Stephen Thompson, Krishna Tangirala, & Michael Eaddy. (2016). A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome. Clinical Lymphoma Myeloma & Leukemia. 17(3). 173–178. 18 indexed citations
14.
Wen, Lonnie, Augustina Ogbonnaya, Adriana Valderrama, et al.. (2016). Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events. Clinical Therapeutics. 38(8). 1880–1889. 7 indexed citations
15.
Blanchette, Christopher, Anthony P. Nunes, Nancy U. Lin, et al.. (2015). Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function. Drugs in Context. 4. 1–10. 18 indexed citations
16.
Başer, Onur, Krishna Tangirala, Wenhui Wei, & Lin Xie. (2013). Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. ClinicoEconomics and Outcomes Research. 5. 497–497. 32 indexed citations
17.
Singh, Anup, et al.. (2013). Achalasia in Downʼs Syndrome: An Atypical Presentation. The American Journal of Gastroenterology. 108. S210–S210.
18.
Eaddy, Michael, et al.. (2012). Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome. Applied Health Economics and Health Policy. 10(6). 431–440. 4 indexed citations
19.
Khorana, Alok A., Mehul Dalal, Krishna Tangirala, & Raymond Miao. (2011). Higher Incidence of Venous Thromboembolism in the Outpatient Versus the Inpatient Setting Among U.S. Cancer Patients. Blood. 118(21). 674–674. 18 indexed citations
20.
Tangirala, Krishna, et al.. (2009). The economic implications of rasburicase treatment in pediatric tumor lysis syndrome patients. Journal of Clinical Oncology. 27(15_suppl). 10050–10050.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Javier Cassinello Breakdown of academic impact, for papers by Aviva G. Asnis-Alibozek Breakdown of academic impact, for papers by Jan Lim Breakdown of academic impact, for papers by Andreea Varga Breakdown of academic impact, for papers by Hyong Woo Moon Breakdown of academic impact, for papers by Pietro Castellan Breakdown of academic impact, for papers by Ho Seok Chung Breakdown of academic impact, for papers by Stefania Mantarro Breakdown of academic impact, for papers by Giorgia Tema
Rankless by CCL
2026